ReviewMediterranean journal of hematology and infectious diseases2020
The Evolving Pharmacotherapeutic Landscape for the Treatment of Sickle Cell Disease.
Review in Mediterranean journal of hematology and infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05530239 (Single-center Pilot Study), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Single-center Pilot Study: Nano-rheological Biomarkers for Patients With Sickle Cell Disease (SCD) Versus Control Subjects (Other Constitutional Red Blood Cell Diseases and Healthy Subjects)
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Interventions for treating leg ulcers in people with sickle cell disease.The Cochrane database of systematic reviews · 2021Pooled it
- Comment on: Heme, the HO-CO-sGC-cGMP pathway, and corpus cavernosum contractility: new insights into the pathophysiology of priapism in sickle cell disease.International journal of impotence research · 2026Article
- Mental health challenges associated with sickle cell disease and strategies to address them: Reflections from a community input panel.Journal of the National Medical Association · 2026Article
- Strategies and innovations in hypertension management for sickle cell patients: A narrative review.Medicine · 2026Review
- Adhesion molecules in focus: mechanistic pathways and therapeutic avenues in sickle cell vaso-occlusion - a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Hydroxyurea Pharmacokinetic Evaluation in Patients with Sickle Cell Disease.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Potassium dynamics in sickle cell anemia: clinical implications and pathophysiological insights.Annals of medicine and surgery (2012) · 2024Review
- Sickle Cell Disease: Current Drug Treatments and Functional Foods with Therapeutic Potential.Current issues in molecular biology · 2024Review
- Review
- Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin.Biomedicines · 2023Review
- Feasibility of Electronic Medication Monitoring Among Adolescents and Emerging Adults with Sickle Cell Disease.Patient preference and adherence · 2023Article
- The APC-EPCR-PAR1 axis in sickle cell disease.Frontiers in medicine · 2023Review
- Blood transfusion and iron overload in patients with Sickle Cell Disease (SCD): Personal experience and a short update of diabetes mellitus occurrence.Acta bio-medica : Atenei Parmensis · 2022Review
- Impact of hemoglobin biophysical studies on molecular pathogenesis and drug therapy for sickle cell disease.Molecular aspects of medicine · 2022Review
- A novel index to evaluate ineffective erythropoiesis in hematological diseases offers insights into sickle cell disease.Haematologica · 2022Article
- Advances in the Management of Sickle Cell Disease: New Concepts and Future Horizons.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2022Article
- The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature.PharmacoEconomics · 2021Review
- Pregnancies and Neonatal Outcomes in Patients with Sickle Cell Disease (SCD): Still a (High-)Risk Constellation?Journal of personalized medicine · 2021Article
- Crizanlizumab for the Prevention of Vaso-Occlusive Pain Crises in Sickle Cell Disease.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2021Review
- Sickle cell disease: progress towards combination drug therapy.British journal of haematology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sickle cell disease (SCD) is an extremely heterogeneous disease that has been associated with global morbidity and early mortality. More effective and inexpensive therapies are needed. During the last five years, the landscape of the pharmacotherapy of SCD has changed dramatically. Currently, 54 drugs have been used or under consideration to use for the treatment of SCD. These fall into 3 categories: the first category includes the four drugs (Hydroxyurea, L-Glutamine, Crizanlizumab tmca and Voxelotor) that have been approved by the United States Food and Drug Administration (FDA) based on successful clinical trials. The second category includes 22 drugs that failed, discontinued or terminated for now and the third category includes 28 drugs that are actively being considered for the treatment of SCD. Crizanlizumab and Voxelotor are included in the first and third categories because they have been used in more than one trial. New therapies targeting multiple pathways in the complex pathophysiology of SCD have been achieved or are under continued investigation. The emerging trend seems to be the use of multimodal drugs (i.e. drugs that have different mechanisms of action) to treat SCD similar to the use of multiple chemotherapeutic agents to treat cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.